Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients

Autor: B V C Kraaijenbrink, E B Wilms, E Leegwater, D J A R Moes, I M Purmer

Publikováno v: The Journal of antimicrobial chemotherapy, 75(6), 1554-1558
Leegwater, E, Kraaijenbrink, B V C, Moes, D J A R, Purmer, I M & Wilms, E B 2020, ' Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients ', The Journal of antimicrobial chemotherapy, vol. 75, no. 6, pp. 1554-1558 . https://doi.org/10.1093/jac/dkaa067
Journal of antimicrobial chemotherapy, 75(6), 1554-1558. Oxford University Press
Journal of Antimicrobial Chemotherapy, 75(6), 1554-1558. OXFORD UNIV PRESS

Objectives To describe the population pharmacokinetics and protein-binding characteristics of unbound ceftriaxone administered as continuous or intermittent infusion. Additionally, to determine the optimal dosing regimen in critically ill patients. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b739dd6236deb207a8a4c0eb7eade6a0
https://pubmed.ncbi.nlm.nih.gov/32129853

Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis. A long-term historical cohort study

Autor: G M, van Dam, C H, Gips, Y, Reisman, K W, Maas, I M, Purmer, J R, Huizenga, B W, Verbaan

Publikováno v: Hepato-gastroenterology. 46(25)

One of the prognostic methods for survival in primary biliary cirrhosis (PBC) is the Mayo model, with a time-scale limited to 7 years. The aim of our study was to assess how major clinical events, signs, several severity assessment methods and Mayo s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d3d8b4101f4f9ec129e90569d5f3c67c
https://pubmed.ncbi.nlm.nih.gov/10228773